Every healthcare finance leader has sat through a vendor pitch promising transformative ROI from some new piece of software. Most of those promises don't survive contact with reality. So when agentic AI vendors start making similarly bold claims about cutting denial rates, accelerating cash flow, and shrinking the cost of running a revenue cycle, a healthy dose of skepticism is the right starting point.
That skepticism is fair, but it shouldn't be the end of the conversation. There's a meaningful amount of independent analysis — separate from any single vendor's marketing — suggesting the financial case for agentic AI in healthcare revenue cycle management is more substantial than the usual hype cycle. Understanding where the real evidence is strong, where it's still thin, and how to evaluate a vendor's specific claims is the difference between a smart investment and an expensive disappointment.
The Size of the Problem Sets the Ceiling on the Opportunity
Before getting to what agentic AI can save, it's worth understanding how much money is actually on the table. Revenue cycle management is an enormous and expensive function. Independent analysis has pegged the cost of running the revenue cycle at roughly 3 to 4 percent of an at-scale health system's total revenue, and collectively, health systems spend more than $140 billion annually on this function alone, with manual processes, fragmented vendor landscapes, and outdated technology contributing heavily to that cost.
Zoom out further, and the broader administrative burden gets even larger. Healthcare spending overall consumes close to a fifth of the U.S. economy, a level that has remained persistently higher, as a share of GDP, than comparably wealthy countries for years according to the Congressional Budget Office's long-running analysis of national health spending trends (source). Administrative costs are a meaningful piece of that gap, and revenue cycle inefficiency — denials, underpayment, delayed collections, duplicate work — is one of the more addressable slices of it, since it doesn't require changing how care is delivered, only how it's billed for.
What the Credible Estimates Actually Say
McKinsey's analysis of agentic AI in the revenue cycle anticipates that AI deployment in this space could lead to a 30 to 60 percent reduction in the cost to collect, alongside faster cash realization and a workforce that's able to refocus on higher-value work rather than administrative tasks. That's a wide range, and the width matters — it reflects genuine uncertainty about how much of this technology's promise translates into reliable, repeatable savings across different organizations, payer mixes, and starting points.
It's also worth distinguishing between vendor-reported numbers and independently verified ones. Plenty of individual case studies report striking results — dramatic reductions in review time, sharp drops in denial rates, multiplied follow-up capacity per staff member — and some of those numbers are likely accurate for the specific organization that reported them. But a single case study from a vendor's own marketing materials is a different category of evidence than a controlled, peer-reviewed, or independently audited result. The honest position is that the directional case for savings is strong and increasingly well-supported, while specific percentage claims from any one vendor deserve the same scrutiny you'd apply to any sales pitch.
Where the Savings Actually Come From
It helps to be concrete about the mechanisms driving these numbers, rather than treating "AI saves money" as a black box.
Fewer denials means less rework. Reworking a single denied claim costs real money in staff time, and industry estimates of that per-claim cost run from the tens of dollars into the low hundreds depending on complexity. Preventing even a modest share of denials before submission compounds quickly across thousands of claims a month.
Faster cash realization improves the time value of money. A claim collected in 30 days instead of 60 isn't just an accounting curiosity — it changes a hospital's actual cash position, which matters enormously for organizations operating on thin margins.
Higher staff throughput without proportional headcount growth. Agentic systems that allow one staff member to manage the exception cases for a larger volume of work change the staffing math for a department, which is where a meaningful share of the reported savings actually originates.
Reduced compliance exposure. While harder to quantify in a spreadsheet, fewer unsupported codes and better-documented appeals reduce the risk of costly post-payment audits and recoupment demands down the line.
A more detailed breakdown of how these mechanisms connect across different revenue cycle functions is available in this overview of agentic AI workflows in healthcare revenue cycle management, which walks through how organizations sequence automation investments to capture this value.
The Workforce Question Deserves a Straight Answer
Any honest discussion of ROI has to address what happens to the people currently doing this work, and the data here is more nuanced than either "AI replaces everyone" or "nothing changes" framing suggests.
A recent federal labor market analysis specifically examined how AI is expected to affect healthcare administrative occupations, finding that AI-based tools making the medical coding process more efficient are expected to moderate demand growth for medical records specialists, while administrative roles handling billing and claims management tasks are expected to see productivity-enhancing effects rather than outright displacement (source). Notably, that same analysis still projects continued employment growth for most of these roles overall, because underlying demand for healthcare keeps growing even as individual tasks get automated — the exception being narrower, more mechanically automatable roles like medical transcription, where federal projections show an actual employment decline tied directly to AI-driven speech recognition.
That distinction matters for the ROI conversation. The most credible business case for agentic AI in RCM isn't "eliminate the billing department." It's "let the same staff handle a larger, more complex claim volume without proportional headcount growth," which shows up financially as cost avoidance rather than dramatic layoffs. Organizations that frame the technology around augmentation rather than replacement also tend to see smoother adoption, since staff are less likely to resist or work around a system they perceive as an existential threat.
Red Flags Worth Watching For
Not every vendor pitch deserves equal trust, and a few patterns are worth treating skeptically.
"Fully autonomous, end-to-end" claims. Multiple independent analyses of the current state of agentic AI in healthcare RCM converge on the same conclusion: full autonomy across the entire revenue cycle isn't realistic yet, given how much payer variability and clinical judgment the work still requires. A vendor promising to eliminate human involvement entirely is overselling.
ROI estimates with no baseline. A percentage improvement is meaningless without a clear statement of what it's being measured against. Ask specifically what the baseline denial rate, days-in-AR, or cost-to-collect was before the deployment, and over what time period the improvement was measured.
No mention of exception handling. If a vendor's pitch glosses over what happens when the system encounters something it can't confidently resolve, that's a sign the demo numbers may not reflect real-world claim complexity.
Pricing models that don't scale with actual value delivered. Some vendors price based on claim volume and expected agentic actions, which aligns their incentives with actual outcomes. Flat licensing fees regardless of performance are a weaker signal of confidence in the product's real-world impact.
Building a Realistic Business Case
For an organization actually evaluating this investment, a few practical steps tend to separate successful adoptions from disappointing ones.
Start with a measurable baseline. Before any deployment, document current denial rates, days in AR, cost-to-collect, and staff time allocation by function. Without this, there's no honest way to measure improvement later.
Pilot in the lowest-risk, highest-volume area first. Back-end functions like AR follow-up and cash posting tend to be the safest starting point, both because the work is repetitive and rules-based and because mistakes there are correctable rather than patient-facing.
Set a realistic timeline. Industry analysts tracking adoption curves suggest organizations that invest seriously now and build on a unified data platform could reach more advanced, systemic automation within roughly two to three years — a faster curve than past healthcare technology adoption cycles, but still a multi-year journey rather than an overnight transformation.
Track both hard and soft metrics. Cost-to-collect and denial rates are the obvious financial metrics, but staff satisfaction, time reallocated to higher-value work, and patient experience improvements matter too, even if they're harder to put a dollar figure on in a board presentation.
The Honest Bottom Line
The financial case for agentic AI in healthcare revenue cycle management is real, but it's not magic, and it's not instant. The strongest evidence points toward meaningful, multi-year reductions in cost-to-collect and denial-driven revenue leakage, concentrated in the back-end, high-volume, rules-based functions where the technology is most mature today. The weakest evidence is in any claim of full end-to-end autonomy, which remains more marketing aspiration than production reality.
For a finance leader deciding whether to invest, the right question isn't whether agentic AI works — the evidence increasingly says it does, in the right places, deployed the right way. The better question is whether your organization has the baseline data, the realistic timeline, and the willingness to treat this as workforce augmentation rather than replacement, because those factors, more than any vendor's feature list, are what actually determine whether the ROI shows up in next year's budget or stays stuck in a pilot program for the next three.
Top comments (0)